Ignite Creation Date:
2024-10-25 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06503211
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-07
Brief Title:
On the Safety Tolerability and Efficacy of UTAA09 Injection in the Treatment of Lymphoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase I Clinical Study on the Safety Tolerability and Efficacy of UTAA09 Injection in the Treatment of Recurrent or Refractory B-cell Non Hodgkins Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main research objective is to evaluate the safety tolerability and pharmacokinetic characteristics of UTAA09 cell preparation in the treatment of relapsedrefractory B-cell non Hodgkins lymphoma patients The secondary research objective is to explore the clinical efficacy of UTAA09 injection after administration and to explore the content of CD19 positive B cells in peripheral blood after UTAA09 injection administration
Detailed Description:
Single dose single arm trial exploring the initial 28 day safety and efficacy of the investigational drug
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None